You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE Test

Expert Perspectives to Recap Kidney Week: Where Are We Now With Chronic Kidney Disease Management?

  1. Over 90% of people living with diabetes and chronic kidney disease (CKD) will develop what?
    Cardiovascular-related complications
    Kidney failure (end-stage kidney disease [ESKD])
    Renal carcinoma
  2. Full results of EMPA-KIDNEY, a kidney outcomes trial of the sodium-glucose cotransporter-2 empagliflozin, were presented during the 2022 American Society of Nephrology (ASN) Kidney Week, and concurrently published. Compared with placebo, empagliflozin slowed kidney disease progression.
    What was unique about the study design of EMPA-KIDNEY?
    Included patients with a urine albumin-to-creatinine ration (UACR) ≥ 300 mg/g
    Included patients at risk of progression to ESKD
    Included patients with estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73m2
  3. Agents within the glucagon-like peptide-1 (GLP-1) receptor agonist class have shown nephroprotective effects in their respective cardiovascular outcomes trials. A post hoc analyses of SUSTAIN-6, the cardiovascular outcomes trial of semaglutide, was presented during the 2022 ASN Kidney Week.
    Semaglutide was shown to reduce the rate of the eGFR slope decline irrespective of what?
    Baseline UACR
    Presence of diabetes
    Baseline eGFR
  4. According to the KDIGO 2022 clinical practice guideline, which of the following drug classes are recommended for patients with CKD and diabetes, for additional heart and kidney protection?
    Biguanides (metformin)
    GLP-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists (MRAs)
    SGLT2 inhibitors